Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma
Open Access
- 22 August 2024
- journal article
- review article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-16
Abstract
Renal cell carcinoma (RCC) is one of the most common tumors that afflicts the urinary system, accounting for 90–95% of kidney cancer cases. Although its incidence has increased over the past decades, its pathogenesis is still unclear. Tumor-associated macrophages (TAMs) are the most prominent immune cells in the tumor microenvironment (TME), comprising more than 50% of the tumor volume. By interacting with cancer cells, TAMs can be polarized into two distinct phenotypes, M1-type and M2-type TAMs. In the TME, M2-type TAMs, which are known to promote tumorigenesis, are more abundant than M1-type TAMs, which are known to suppress tumor growth. This ratio of M1 to M2 TAMs can create an immunosuppressive environment that contributes to tumor cell progression and survival. This review focused on the role of TAMs in RCC, including their polarization, impacts on tumor proliferation, angiogenesis, invasion, migration, drug resistance, and immunosuppression. In addition, we discussed the potential of targeting TAMs for clinical therapy in RCC. A deeper understanding of the molecular biology of TAMs is essential for exploring innovative therapeutic strategies for the treatment of RCC.Keywords
Funding Information
- National Natural Science Foundation of China (82072835)
This publication has 126 references indexed in Scilit:
- FOXK1 upregulation is correlated with tumor progression and tumor associated macrophages infiltration in renal cell carcinomaMolecular Carcinogenesis, 2023
- Combining expression of RNF43 and infiltration level of CD163+ tumor associated macrophage predicts prognosis of clear cell renal cell carcinomaCancer Medicine, 2022
- Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patientsCancer Immunology, Immunotherapy, 2021
- Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10Cancer Immunology, Immunotherapy, 2020
- Targeting tumor‐associated macrophages: A potential treatment for solid tumorsJournal of Cellular Physiology, 2020
- CSF1R‐ and SHP2‐Inhibitor‐Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor‐Associated MacrophagesAdvanced Materials, 2019
- Apolipoproteins and cancerCancer Medicine, 2019
- Crosstalk between cancer and immune cells: Role of tumor‐associated macrophages in the tumor microenvironmentCancer Medicine, 2019
- Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor‐conditioned macrophagesEuropean Journal of Immunology, 2019
- Long non‐coding RNA cox‐2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarizationJournal of Cellular Biochemistry, 2017